Tamro Sweden  
The year in Brief
  Letter to the Shareholders
  Shares and Shareholders
Tamro Sweden
  Tamro Denmark
  Tamro Finland
  Tamro Norway
  Tamro Estonia
  Tamro Latvia
  Tamro Lithuania
  Tamro Russia
  Tamro MedLab
 
  Download Centre
   
 

This web annual report has been abridged and modified for ease of use. The complete annual report will be released during week 13, after which you can also download the printable PDF version.

  • The Swedish pharmaceutical market continued to grow at 6.7%.
  • Tamro Sweden's net sales came to EUR 1,487.0 million (1,573.8). In local currency net sales grew by 3.5%.
  • Internally Tamro Sweden will concentrate on efficiency of operations and the overall quality of services.

Operating environment and markets

The Swedish pharmaceutical market continued to grow at 6.7% in 2001. Parallel importers' share of the aggregate sales grew by over 12% and was 9.3% of the whole market. Pharmaceutical sales in terms of pharmacy purchasing prices rose to EUR 2,335 million.

In June, the Swedish Competition Authority issued a decision stating that the plans elaborated by Apoteket AB to develop its operations do not violate competition laws. After Apoteket AB published its plan in autumn 2000, several complaints were filed with the Swedish Competition Authority. Apoteket then revised its original plans so that its branching out will not compete with the distribution operations of Tamro and other pharmaceutical companies. The Swedish Competition Authority stressed that pharmaceutical wholesalers will continue to be responsible for distribution to all pharmacies.

During autumn 2001 the Swedish government proposed that pharmacies switch from expensive products to the cheapest similar products. Thus generic substitution will be mandatory unless the prescriber actively forbids it.

Financial performance and operations

  2001 2000 Change
Net sales, EUR million 1487.0 1573.8 -5.5%
Employees 519 578 -10.2%

Tamro Sweden's net sales came to EUR 1,487.0 million (1,573.8). In local currency net sales grew by 3.5%. Pharmaceutical sales accounted for 80% of the total sales. Tamro Sweden's operating profit improved, which can be explained by higher sales, compensation related to year 2000 and better cost control in operating costs. IT costs have decreased substantially compared to the previous year. Tamro Sweden employed an average of 519 (578) people in 2001.

Internet-based information services both to suppliers and pharmacies were developed during the year. Tamro Web Analysis is designed for suppliers and it offers an information system for stocks and sales. The suppliers have access to sales statistics, transactions, back order information and certain key performance indicators. All information is updated on a daily basis.

Tamro Web Direct, another Internet-based application, has been developed to complement Tamro Sweden's customer service provided to pharmacies. Each pharmacy can easily and quickly find valuable real time operational information about orders, deliveries, back orders and stocks.

Outlook for 2002

The pharmaceutical market will continue to grow, but, according to authorities' estimates, at a slower pace, the focus being on healthcare cost containment. Internally Tamro Sweden will concentrate on efficiency of operations and the overall quality of services in order to guarantee added value for customers' operations. The development of the Tamro's highly competitive business information systems will continue at a rapid pace to provide customers with real time business information.

 
Net sales Graph  
Personnel Graph  
Share of consolidated net sales Graph  
     
Print all graphs Printable version  
 
PDF document
 
Tamro Web Annual Report 2001,
Copyright © Tamro Corporation, All rights reserved